Advanced therapies are changing what is possible in medicine. Cell therapies, gene therapies and tissue-engineered products are creating new opportunities for patients with serious, rare and complex diseases. However, they also bring manufacturing, testing and quality challenges that are very different from traditional pharmaceutical products.
For QA and QC teams, this creates a critical leadership opportunity. The role of quality is no longer simply to review documents, approve deviations or release batches. In advanced therapies, QA and QC professionals are helping organisations move faster by building quality into innovation from the beginning.
That distinction matters. Faster innovation does not mean weaker controls. It means smarter quality systems, earlier risk assessment, better data, stronger cross-functional collaboration and phase-appropriate GMP thinking. The European Medicines Agency describes advanced therapy medicinal products as medicines for human use based on genes, tissues or cells, offering important opportunities for treating disease and injury. These products may be scientifically advanced, but they still depend on disciplined quality oversight.
Quality as an Enabler, Not a Barrier
In fast-moving advanced therapy companies, QA can sometimes be misunderstood as a function that slows progress. In reality, strong QA helps teams avoid delays by identifying risks early, preventing rework and creating a clear pathway from development to clinical and commercial manufacturing.
When quality input comes too late, projects can be delayed by avoidable problems: incomplete validation strategies, weak supplier qualification, unclear critical quality attributes, poorly defined specifications, data integrity gaps, inadequate contamination controls or analytical methods that are not ready for release decisions.
A more mature approach is to embed QA into development, technology transfer, process design, clinical manufacturing and scale-up planning. This allows quality professionals to challenge assumptions before they become expensive problems.
For QA leaders, the message to organisations should be simple: quality does not slow innovation when it is integrated early. It slows innovation when it is added late.
Phase-Appropriate Quality Systems
Advanced therapy development often happens under pressure. Small patient populations, urgent clinical need, limited starting material and complex manufacturing processes can all create timelines that feel compressed. That is why phase-appropriate quality systems are essential.
Phase-appropriate does not mean informal or inconsistent. It means the level of control should be appropriate to the stage of development, the product risk and the intended use. Early clinical manufacturing may not require the same level of process validation as commercial production, but it still requires clear procedures, trained people, traceable materials, controlled records and justified decisions.
The FDA’s cellular and gene therapy guidance page includes current and recent guidance on topics such as CMC information for human gene therapy INDs, potency assurance, manufacturing changes and comparability, safety testing and expedited programmes for regenerative medicine therapies. This shows how wide-ranging the quality considerations are for advanced therapy development. QA and QC teams need to understand not only GMP, but also CMC strategy, product characterisation, analytical readiness and lifecycle control.
Risk-Based Thinking Supports Speed
One of the most valuable tools QA brings to advanced therapies is structured quality risk management. ICH Q9(R1) provides a framework for quality risk management across the pharmaceutical lifecycle, supporting science-based and risk-based decision-making. In advanced therapies, this is essential because not every risk can be eliminated, and not every control carries the same weight.
QA teams can help organisations focus energy where it matters most: patient safety, product identity, potency, sterility, purity, traceability, chain of custody, process consistency and data integrity. By applying risk-based thinking, QA can help teams avoid both under-controlling critical risks and over-burdening lower-risk activities.
This is particularly important in areas such as raw material control, viral vector supply, aseptic processing, cell handling, cryopreservation, shipping, environmental monitoring and rapid release testing. A risk-based approach helps teams prioritise resources and make faster decisions without compromising compliance.
Building Quality Into Process Design
Advanced therapies are often difficult to manufacture consistently. Living cells, biological variability, short shelf lives, patient-specific starting material and complex analytical methods all make process control more challenging.
This is why QA and QC should be involved in process design from the outset. The quality team should help define critical process parameters, critical quality attributes, acceptable ranges, sampling strategies, hold times, operator controls, environmental requirements and documentation expectations.
Good process design also supports future scalability. A process that depends heavily on manual intervention may work during early development but become difficult to control as demand increases. QA can help teams consider closed systems, automation, electronic batch records, standardised training and robust deviation pathways early enough to prevent scale-up issues later.
The EMA notes that the European Commission published GMP guidelines specific to ATMPs, with adaptations designed to ensure a high level of quality and patient protection. For QA teams, this reinforces the importance of applying GMP in a way that recognises the specific nature of advanced therapies.
QC Innovation Is Just as Important
Innovation in advanced therapies is not only about manufacturing. QC laboratories are also under pressure to evolve. Traditional release testing models may not always suit products with short shelf lives or urgent clinical use. Long assay turnaround times can delay treatment, particularly for patient-specific therapies.
QC teams are therefore playing a growing role in method development, assay qualification, rapid microbiological methods, potency strategy, reference standards, sample management and data review efficiency. The challenge is to improve speed while maintaining scientific confidence.
Potency testing is a particular area of focus. For cell and gene therapy products, potency methods must be meaningful, reliable and connected as far as possible to biological activity. FDA guidance listings include potency assurance and manufacturing comparability topics, both of which are central to the quality control of cellular and gene therapy products.
QC leaders can support faster innovation by asking practical questions early. Can the method support timely batch release? Is it robust enough for repeated use? Are analysts trained? Is the sample volume realistic? Is the assay suitable for the product’s stage of development? Will the method remain useful as the process changes?
Digital Quality Systems Can Reduce Friction
Advanced therapy manufacturing generates large amounts of data, from chain of identity and chain of custody records to environmental monitoring, batch records, QC results, equipment logs, deviations and cold chain data. Manual systems can quickly become a bottleneck.
Digital quality systems can support faster review, better traceability and improved data integrity. Electronic batch records, laboratory information management systems, validated quality management systems, and integrated manufacturing platforms can all help QA and QC teams work more efficiently.
However, digital tools must be implemented carefully. QA should be involved in system validation, user access controls, audit trails, data governance, electronic signatures and change control. A digital system that is poorly implemented can create more risk than the paper process it replaces.
Managing Change Without Losing Control
Advanced therapy development involves constant learning. Processes evolve, analytical methods improve, suppliers change, manufacturing sites expand, and automation may be introduced. Without strong change control, innovation can quickly become uncontrolled variation.
QA teams support faster innovation by making change control efficient, risk-based and scientifically grounded. The goal is not to create unnecessary administrative barriers. The goal is to ensure that changes are assessed for their potential impact on product quality, patient safety, regulatory commitments and comparability.
Comparability is especially important when manufacturing processes change during development or before commercialisation. Teams need evidence that the product remains appropriately controlled after a change. QA can help define what evidence is required and ensure the decision-making process is documented.
The Talent Opportunity for QA and QC Professionals
For QA and QC talent, advanced therapies offer a chance to work at the leading edge of medicine. These roles require technical curiosity, strong GMP knowledge, scientific judgement and the confidence to work in cross-functional teams.
Managers should look for professionals who can balance speed and discipline. The best QA and QC specialists are not those who simply quote procedures. They understand why controls exist, how processes behave and where the real risks sit. They are comfortable working with manufacturing, process development, regulatory affairs, supply chain, clinical teams and senior leadership.
For people building careers in QA and QC, advanced therapies are a powerful growth area. Skills in aseptic processing, contamination control, data integrity, QC method lifecycle management, validation, supplier quality, digital quality systems and quality risk management will continue to be highly valuable.
Final Thoughts
Faster innovation in advanced therapies depends on strong QA and QC leadership. Quality teams are helping organisations move quickly by preventing avoidable delays, designing better systems, strengthening data, improving release readiness and supporting risk-based decisions.
The future of advanced therapies will not be shaped by speed alone. It will be shaped by the ability to move quickly while maintaining trust. Patients, regulators, clinicians and manufacturers all depend on that trust.
For QA and QC teams, this is the opportunity: to be the function that protects patients while enabling progress. In advanced therapies, quality is not the opposite of innovation. Done well, it is one of the strongest drivers of it.